• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Liposome-based anchoring and core-encapsulation for combinatorial cancer therapy

    2022-09-15 03:10:50QingqingXiaoXiaotongLiChangLiuYiYangYuqiHouYingWangMengxiangSuWeiHe
    Chinese Chemical Letters 2022年9期

    Qingqing Xiao, Xiaotong Li, Chang Liu, Yi Yang, Yuqi Hou, Ying Wang, Mengxiang Su,Wei He

    School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China

    ABSTRACT Downregulated pro-apoptotic protein in cancer cells compromises the chemotherapy by a cytotoxic drug.Here, we report co-delivery of a pro-apoptotic protein, caspase 3 (Cas 3), and cytotoxic agent, oridonin(ORD), for synergistic cancer treatment, using a method of liposome-based anchoring and core encapsulation.First, ORD is modified with hyaluronic acid (HA) to improve its solubility.Then, the targeted codelivery system is prepared by assembling the conjugate HA-ORD onto the Cas 3-loaded liposomes, which the surface HA can target the CD44 receptor on cancer cells. In vitro, the co-loaded liposomes (120 nm)are specifically taken up by 4T1 cells and endow a 1.5-fold increase of Cas 3.After intravenous injection into the tumor-bearing mice, the liposomes accumulate in the tumor with high efficacy and significantly inhibit tumor growth via promoting apoptosis and anti-proliferation of cancer cells.Mechanistically, the co-delivery works synergistically by upregulating the activated Cas form, cleaved-Cas 3.

    Keyword:Liposomes Co-delivery Chemotherapy Pro-apoptotic protein Tumor targeting

    Breast cancer was the most commonly diagnosed cancer globally, accompanying approximately 2.26 million cases [1].The cancer occurrence mainly results from cell apoptosis disorder, which inhibits pro-apoptotic signals in tumor cells while anti-apoptotic proteins are upregulated.Two initiation pathways are frequently involved in cell apoptosis: activating death receptors through external damage and triggering the release of cytochrome c and other substances from the mitochondria via intrinsic pathways [2].Clinical evidence shows that the combination of traditional chemotherapy and pro-apoptotic agents can synergistically elevate the survival rate of cancer patients [3].Furthermore, caspase 3 (Cas 3)is a significant mediator of cancer cell apoptosis after exposure to cytotoxic drugs or radiotherapy [4,5].Therefore, we theorized that combinatorial use of Cas 3 and the cytotoxic drug could represent a promising regimen to combat cancer.

    Poor drug delivery to the tumor site is a significant limitation that hinders cancer treatment.Drug carriers can improve tumor targeting because of their small size and penetration inside the diseased area [6].Liposomes (Lips) are enclosed spherical vesicles composed of one or more lipid bilayers [7].Lips are emerging as promising carriers to enhance drug delivery due to the advantages, including high payload capacity, prolonged blood circulation time, targeting ability to the disease site, and ignorable toxicity to the body [8–10].Over 20 liposomal formulations were approved for clinical use [11].In this study, we co-delivered oridinon (ORD) and Cas 3 using Lips for the combined treatment of breast cancer in 4T1 tumor-bearing mice.ORD is a natural compound with poor solubility isolated from the traditional Chinese medicine Rubescenin [12].It has a robust ability to fight against various cancers such as liver cancer, prostate cancer, and breast cancer [13–17].Briefly, ORD was conjugated with hyaluronic acid(HA) to improve its solubility.After that, the co-delivery system,hybrid nanoparticles (HNPs), was prepared by assembling the HAORD conjugate onto the Cas 3-loaded liposomes, which the conjugate hydrophobic segment anchored into the liposomal membrane and, meanwhile, the HA part located on the HNPs surface to target CD44 receptor on cancer cells (Scheme 1) [18,19].The targeted co-delivery system efficiently accumulated in the tumor and inhibited the tumor growth synergistically through upregulation of the activated Cas 3 form, cleaved-Cas 3.

    Scheme 1.(A) Preparing the co-delivery system (HNPs) by anchoring the conjugate HA-ORD onto Cas 3-Lips.(B and C) Purposed performance in vivo.After intravenous injection, (B) HNPs accumulate in the tumor, and (C-1) target tumor cells through CD44-HA receptor-ligand interaction, (C-2) release the two active ingredients inside the cells, and (C-3) synergistically activate Cas-3 pathway to promote apoptosis of tumor cells.

    First, the conjugate HA-ORD was synthesizedviaesterification reaction as described in previous report [20].Cas 3-Lips were prepared by the reverse-phase evaporation method [21].As depicted in Table S1 (Supporting information), the protein-encapsulated Lips have a diameter of 120 nm and a protein encapsulation efficacy(EE) of greater than 50% in the formulations with protein/lipid ratios (w/w) of 1:10–1:30.The protein encapsulation was identified by SDS-PAGE, in which the demulsification separated protein bands significantly weakened compared with the control (Fig.1A).The protein/lipid ratios had a modest influence on the diameter and EE; however, the ratio increase reduced the drug-loading capacity from approximately 5% to 2%.Accordingly, the Lip formulation with a protein/lipid ratio of 1:10 was selected for further study due to its highest drug payload.Then, the co-delivery system, HA-ORD/Cas 3-Lip HNPs, was prepared by assembling the conjugate onto the Cas 3-Lips.The particle size of HNPs increased from 113 nm to 274 nm with a gradual decrease in the zeta potential as HA/lipid ratio elevated from 1:4 to 2:1 (w/w) (Table S2 in Supporting information).To investigate the co-assembly, we conducted the FRET study for the HNPs with various HA/lipid mass ratios by using FITC as a donor conjugated with HA-ORD and Rho as the acceptor encapsulated in the Lips.With the increase of Rho-Lips in the HNPs,the maximal fluorescence intensity of the acceptor (Rho) at 575 nm increased significantly.In comparison, the maximal fluorescence intensity of the donor (FITC) at 515 nm decreased, indicating the FRET occurrence (Fig.1B).FRET is a potent tool for studying the interaction between two materials by labeling fluorescent donor and acceptor [22–24].Consequently, the assembly of the conjugate and the Lips was confirmed.

    The HNPs with the HA/lipid ratio of 1:2 were selected for further study due to the smaller diameter (~118 nm) and higher loading of Cas 3.TEM test displayed that the Lips and HNPs had spherical morphology (Fig.1C).The drug EE% and DL% in total in HNPs was 48.75% and 7.92%, respectively, which the DL% of Cas 3 and ORD was 4.75% and 3.17%, respectively.Incubation in 10% serum for 12 h imposed a slight alteration in diameter, surface charge, and morphology of the two nanoparticles (Figs.1D–F).However, their PDI and surface potential gradually increased during the incubation period of 12–24 h.It is worth noting that these increase from HNPs was compromised compared with Lips.The data demonstrated that the conjugate assembly could improve the serum stability of Lips.Release study shows that 60%–80% of encapsulated dye carboxyfluorescence (CF) in the core of liposomes from HNPs was released at 2 h under different pH conditions (Fig.1G), indicating that HNPs can effectively release the encapsulated drug.Meanwhile, the HAORD release from HNPs was pH-dependent, increasing pH value resulting in a faster release.Interestingly, the release at pH 5 was significantly slower than at pH 6.8 and 7.4.The profile demonstrated that the conjugate has an elevated force to anchor onto liposome under low pH conditions and might help maintain the structural stability of HNPs in the acidic tumor microenvironment (Fig.1H).

    Next, the uptake study in 4T1 cells was performed by flow cytometry.As displayed in Figs.S1 and S2 (Supporting information),the uptake of the conjugate and the two nanoparticles was timedependent in a specific period.Especially, HNPs reached their maximal uptake at 1 h after incubation, while Lips did not get the most significant uptake at even 4 h (Fig.S1B), indicating faster endocytosis of HNPs.The further experiment showed that the uptake of HNPs was concentration-dependent (Figs.S1C and D).

    Fig.1.Characterization: (A) SDS PAGE of free Cas 3 and separated Cas 3 after Cas 3-Lips demulsification.(B) Fluorescence emission spectra of FITC-HA-ORD, Rho-Lips and FITC-HA-ORD/Rho-Lip HNPs with various HA/lipid mass ratios. λex=450 nm.(C) TEM images of Cas 3-Lips and HA-ORD/Cas 3-Lip HNPs.The scale bar is 100 nm.(D and E)Serum stability of Lips and HNPs in 10% FBS at 37°C.The change of the (D, E) morphology, size, PDI, and (F) ζ-potential of Lips and HNPs.(G) In vitro release of CF from CF-labeled HNPs at 37°C.CF was encapsulated in the cores of HNPs.(H) In vitro release of FITC-HA-ORD from HNPs.Data are presented as mean ± SD (n=3).The samples collected at specified time intervals were placed in a 96-well plate to measure fluorescence intensity using a fluorescence spectrometer (CF, λex=492 nm and λem=515 nm;FITC, λex=490 nm and λem=520 nm).

    The CD44 receptor is overexpressed on various tumor cells [25],and HA is a specific ligand for CD44 [26–28].To verify CD44 role in HNPs uptake, we saturated the surface CD44 receptors by preincubating 4T1 cells with excess free HA.Flow cytometry assay showed that Rho-HNPs uptake in the pretreated cells was significantly reduced compared with unsaturated cells (P<0.05, Fig.S1E).Laser scanning confocal microscope (CLSM) observation indicated HA pretreatment resulted in weaker intracellular fluorescence intensity (Fig.S1F).To further prove the targetability of HNPs to cancer cells, we investigated the uptake in 4T1 cells and the control cell line without over-expressing CD44 receptors, NIH 3T3.As expected, the uptake of HNPs in 4T1 cells was significantly higher than that in NIH 3T3 cells under fixed FITC or Rho concentration conditions (Figs.S1G and H).These results confirmed that the conjugate anchoring promoted the Lips uptake in tumor cells through the specific HA/CD44 ligand/receptor affinity.

    To test the anti-tumor activity, we incubated preparations with 4T1 cells.Cas 3-Lips display improved cytotoxicity to 4T1 cells at the protein concentrations of ≥2.5 μg/mL compared with free Cas 3 (Fig.S3A in Supporting information), owing to that liposome encapsulation can improve the protein stability and promote the uptake.The conjugate HA-ORD had concentration-dependent cytotoxicity.The ORD in the conjugate could be released due to the ester-bond degradation by the cytosol esterase [29].Therefore, the conjugate HA-ORD demonstrated toxicity against cancer cells.In contrast, HNPs showed the most profound cytotoxicity among the preparations at specific drug concentrations (31.3 μg/mL, Fig.S3B in Supporting information), accompanied with a 2-fold cytotoxicity increase in contrast with the simple combination of Cas 3 and the conjugate.

    The synergy effect was investigated by measuring the cytotoxicity of HNPs with different mass ratios of HA/lipid (2:1, 1:1, 1:2,1:4) and calculating the combination index (CI) by Compusyn software.The CI values from formulations with ratios of 2:1, 1:1, 1:2 are<1 at a specific low inhibition rate (Fa), while, at all Fa, the CI from 1:4 ratio is not great than 1 (Figs.S3C and D in Supporting information), indicating its improved synergy.As a result, the HNPs with HA/lipid of 1:4 were selected for further study.

    Apoptosis determination displayed that HA-ORD and Cas-Lips had 60% and 10% of 4T1 cell apoptosis after 48 h incubation.However, the simple combination formulation did not lift the apoptosis rate (60%) compared with HA-ORD.In contrast, HNPs exhibited an 83% apoptosis rate and thus indicated the co-delivery allowed enhanced apoptosis of cancer cells (Figs.S3E and F in Supporting information).

    Then, the level of critical proteins in the apoptosis process was determined by WB.Cas 3 exists in an inactive precursor form in cells.After being activated, it is cleaved at an aspartate and is broken down into cleaved-Cas 3 [30].Finally, cleaved-Cas 3 initiates the downstream protein pathway or blocks DNA repair to induce cell apoptosis [31–33].Therefore, we determined the expression level of Cas 3 and cleaved-Cas 3 after preparation incubation.As depicted in Fig.2, the dosing with HNPs endorsed the highest level of Cas 3 and cleaved-Cas 3 in tumor cells, verifying the intracellular delivery of Cas 3 and its activation.Also, the conjugate induced Cas 3 expression and implied its potential ability to promote tumor cell apoptosis.

    Fig.2.Expression of the pro-apoptotic protein in 4T1 cells: (A) WB analysis of Cas 3 and cleaved-Cas 3 expressions in cells after treatment with preparation for 48 h at an ORD concentration of 0.5 mg/mL or Cas 3 concentration of 10 μg/mL. β-Actin was used as a loading control.Dark bands indicate protein expression.Quantitative analysis of the expression of (B) Cas 3 and (C) cleaved-Cas 3.mean ± SD, n=3, ?P<0.05, ??P<0.01, ???P<0.001.Preparations: 1, saline; 2, free Cas 3; 3, HA-ORD; 4, HNPs.

    To study the biodistribution, we labeled fluorescence probe DiR (DiIC 18 (7); 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide) to the nanoparticles for imaging [34].After intravenous injection,in vivoimaging of 4T1 tumor-bearing mice at specific time points was executed.Both DiR-Lips and DiR-labeled HNPs effectively accumulated at the tumor site for 24 h period compared with free DiR (Fig.3).Whereas the tumor accumulation of DiR-labeled HNPs, especially at 24 h post-injection, was greater than that of DiR-Lips (P<0.05,Fig.3C).Ex vivoimaging for separated major tissues collected at 24 h further verified that DiR-labeled HNPs had improved tumortargeting ability over DiR-Lips (Fig.3B).These results indicated that the conjugate anchoring promoted the tumor accumulation of Lips and prolonged the residence time.

    Fig.3.Tumor targeting in vivo: (A) In vivo fluorescence imaging of 4T1 tumor-bearing mice after i.v.injection of DiR-labeled preparations at the dye dose of 0.5 mg/kg,according to the body weight.(B) Ex vivo fluorescence images of important tissues were collected at 24 h post-injection.(C) Quantitative analysis of tumor accumulation at different time points (n=3, ?P<0.05, ??P<0.01).

    To study the anti-tumor efficacy, we intravenously administered different preparations to 4T1 tumor-bearing mice every 3 days for 5 doses in 18 days.The tumor volume at 18 days in the salineor free Cas 3-treated group increased by>10-fold compared to that at 0 day, while the tumor volumes in the group treated with HA-ORD group or the physical mixture (free Cas 3 plus HA-ORD)group has 7-fold growth.Significantly, the tumor volume from the groups dosed with HNPs at low or high does exhibited a 5-fold increase and demonstrated significant tumor growth inhibition (Fig.4A).The animal’s body weight in all groups did not decline and,instead, increased at a steady rate (Fig.4B).These results indicated that HA-ORD and HNPs safely regressed the tumor growth in 4T1 tumor-bearing mice, whereas HNPs had improved inhibition.

    The cancer-cell apoptosis in the isolated tumors was examined by TUNEL and Ki67 assay [35].Positive cells shown in TUNELstained sections were most profound in the groups treated with high or low doses of HNPs, followed by the groups treated with preparations containing HA-ORD (Fig.S4 in Supporting information).Quantified determination displayed that HNPs treatment allowed a 50% apoptosis rate in the tumor cell, 5 folds as great as saline treatment.The apoptosis rate of the two groups dosed with preparations containing HA-ORD, HA-ORD, and physical mixture, reached 30% as well (Fig.4C).The apoptosis result was confirmed by the anti-proliferation determination by Ki67 assay (Fig.4D and Fig.S4).The H&E staining assay further demonstrated that the fewest cell numbers were observed in the tumor treated with HNPs (Fig.S4).

    Fig.4. In vivo anti-tumor activity: (A) Tumor-volume growth curves and (B) body-weight change profiles of 4T1 tumor-bearing mice (mean ± SD, n=7).Quantitative analysis of (C) apoptosis and (D) proliferation of tumor cells (mean ± SD, n=3).(E) Western blot analysis of Cas 3 and cleaved-Cas 3 expression in the isolated tumors.Preparations:1, saline; 2, free Cas 3; 3, HA-ORD; 4, physical mixture of Cas 3 and HA-ORD; 5, HNPs. β-Actin was used as a loading control.Dark bands indicate protein expression.Quantified expression of (F) Cas 3 and (G) cleaved-Cas 3 (mean ± SD, n=3).The preparations (0.2 mL) were injected to 4T1 tumor-bearing mice via tail veins every 3 days at an ORD dose of 5 mg/kg or a Cas 3 dose of 150 μg/kg, according to the body weight.HNPs were administrated at two doses of ORD/Cas 3, 5 mg/150 μg/kg, and 7.5 mg/225 μg/kg.?P<0.05, ??P<0.01, ???P<0.001.

    We hypothesized that the tumor-suppressor effect of HNPs was directly related to the delivery and activation of Cas 3.Accordingly,the protein in the isolated tumors was determined by WB assay.Administration with low dose HNPs increased the Cas 3 level by 50% compared with treatment with other preparations (P<0.05,Figs.4E and F).Moreover, the activated Cas 3 form, cleaved-Cas 3,in the group dosed with low dose HNPs raised by approximately 2 folds compared to that from the saline-treated group (P<0.001,Figs.4E and G).The results indicated that the HNPs could effectively deliver Cas 3 into the tumor.

    Overall, HNPs played a significant therapeutic role in the 4T1 breast cancer model by inhibiting tumor growth and promoting tumor cell apoptosis.

    In this study, we demonstrated that the liposome-anchored strategy was promising to promote the co-delivery of active components with high molecular weight.Co-delivery of small molecular drugs using drug carriers has obtained breakthroughs, as evident by the approval of Vyxeos liposomes co-loading daunorubicin and cytarabine to treat acute myeloid leukemia in 2017 [36].However, co-delivery of two molecules with a high molecular weight with carriers is still a considerable challenge due to their limited space for loading.To enlarge the loading space, researchers incorporated cationic materials, such as polyethyleneimine (PEI)and dioleoyl phosphatidyl ethanolamine, into the liposomes to condense the second macromolecular drug on the surface [37].Nonetheless, their incorporation often induces significant toxicity to the body and hinders the translation of the co-delivery system.Herein, we found that the strategy of liposome-based anchoring and core encapsulation enabled the co-delivery of the two active molecules without additional cationic materials.The functional protein was encapsulated in the core of liposomes and whereas the second drug-polymer macromolecule was anchored onto the liposomes via inserting the hydrophobic groups inside the lipid membrane.As well known, most drug-polymer or antibodydrug conjugate has hydrophobic side or residues on their structure [38].Consequently, we believe the current approach is a universal platform to co-deliver polymer-based conjugate/prodrug and biopharmaceuticals.

    The anchoring allowed the liposomes to have enhanced targeting ability to the tumor (Fig.3).HA-ORD-anchored liposomes possessed a 50% increase of tumor accumulation over the liposomes.The profound tumor accumulation is mainly ascribed to the ligand/receptor affinity of HA/CD44 that allowed HNPs to target the tumor tissueviapotentially overcoming the shear forces of blood flow [39,40].Moreover, the conjugate anchoring led to an increase in the negative charge of Lips (Table S2 in Supporting information) and, as a result, could potentially reduce the adhesion of blood proteins to nanoparticles, thereby protecting the nanoparticles from excessive exposure to blood proteins and extending the circulation time [41].Third, the congruence principle might also contribute to the tumor accumulation because HNPs have rich HA on their surface, while a large HA matrix distributes in the tumor.

    Various approaches were employed to improve the stability and performance of liposomesin vitroandin vivo, including nanoparticle-coating [42], polymer-stabilization by covalently linking a polymer to the head groups of lipids [43], and embedding liposomes inside another nanodevice [44].These reported strategies either impaired the biocompatibility of liposomes or limited their translation due to the complicated preparation process.A previous report indicated that the surface coating could reduce the membrane fluidity of liposomes and enhance liposome stabilityin vivo[45].The conjugate anchoring might decrease the membrane fluidity of liposomes as well.Consequently, our HA-based anchoring represents a promising strategy to improve the use of liposomes as drug carriers.

    Co-delivery of Cas 3 and ORD is promising to inhibit tumor growth.Cas 3 is the final apoptosis executor of cancer cells and is downregulated, which has become one critical restriction for chemotherapy in cancer treatment [46,47].Though the two therapeutics are entirely different in water solubility, molecular weight,and stability, the developed HNPs could co-load the Cas 3 and the cytotoxic ORD and precisely deliver them to cancer cells.The results displayed that the two therapeutics worked synergistically to combat cancer.The study offers a route to improve chemotherapy.

    In summary, a liposome-based anchoring and core encapsulation strategy enables targeted co-delivery of two therapeutics,the conjugate HA-ORD and Cas 3, to the tumor, allowing efficient anti-tumor activities by suppressing tumor growth and enhancing apoptosis of tumor cells.Moreover, the conjugate anchoring confers positively targeting ability on liposomes, expands their drugloading capacity, and provides the potential to facilitate the utilization of liposomes as drug carriers.

    Declaration of competing interest

    There are no conflicts to declare.

    Acknowledgments

    This work was supported by the National Natural Science Foundation of China (Nos.81872823, 81872833 and 82073782), the Double First-Class (No.CPU2018PZQ13) of the CPU, the Shanghai Science and Technology Committee (No.19430741500), the Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine(No.zdsys-202103).

    Supplementary materials

    Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2022.01.083.

    欧美zozozo另类| 国产欧美日韩精品一区二区| 欧美最新免费一区二区三区 | 在线视频色国产色| 国产精品三级大全| 午夜精品在线福利| 国产aⅴ精品一区二区三区波| 国产精品99久久久久久久久| av国产免费在线观看| 97超视频在线观看视频| 国产av不卡久久| 国模一区二区三区四区视频| 精品一区二区三区视频在线 | 美女高潮喷水抽搐中文字幕| 一本久久中文字幕| 欧美一级a爱片免费观看看| 日本成人三级电影网站| 香蕉av资源在线| 夜夜爽天天搞| 国产av一区在线观看免费| 又黄又爽又免费观看的视频| 男女下面进入的视频免费午夜| 观看美女的网站| 精品无人区乱码1区二区| 国产精品电影一区二区三区| 99久久久亚洲精品蜜臀av| 久久久久久久久大av| 亚洲欧美日韩卡通动漫| 亚洲精品乱码久久久v下载方式 | 国产真实乱freesex| 最近最新中文字幕大全电影3| 一个人看的www免费观看视频| 中文字幕人成人乱码亚洲影| 中文字幕熟女人妻在线| 无人区码免费观看不卡| 在线播放无遮挡| 日韩人妻高清精品专区| 乱人视频在线观看| 蜜桃亚洲精品一区二区三区| 国产成+人综合+亚洲专区| 悠悠久久av| 久久精品影院6| 午夜精品在线福利| 成人一区二区视频在线观看| 波多野结衣高清无吗| 亚洲精品国产精品久久久不卡| 麻豆国产av国片精品| 夜夜躁狠狠躁天天躁| 欧美日韩黄片免| 美女高潮喷水抽搐中文字幕| 国产麻豆成人av免费视频| 美女被艹到高潮喷水动态| 不卡一级毛片| 99精品欧美一区二区三区四区| 高清毛片免费观看视频网站| 成人欧美大片| 国产男靠女视频免费网站| 嫩草影院精品99| 亚洲人成电影免费在线| 色综合婷婷激情| 国产精品久久久久久久电影 | 性色avwww在线观看| 国内精品久久久久久久电影| 黑人欧美特级aaaaaa片| 精品一区二区三区av网在线观看| 又爽又黄无遮挡网站| 色尼玛亚洲综合影院| 99久久99久久久精品蜜桃| 欧美又色又爽又黄视频| 日日干狠狠操夜夜爽| 婷婷丁香在线五月| 激情在线观看视频在线高清| 91麻豆精品激情在线观看国产| 久久精品91无色码中文字幕| 国产探花在线观看一区二区| 12—13女人毛片做爰片一| 长腿黑丝高跟| 中文字幕人成人乱码亚洲影| 18禁裸乳无遮挡免费网站照片| 中文字幕人妻熟人妻熟丝袜美 | 狂野欧美白嫩少妇大欣赏| 午夜视频国产福利| 国产精品影院久久| 欧美激情在线99| 熟女少妇亚洲综合色aaa.| 国产精品国产高清国产av| 热99在线观看视频| 午夜精品在线福利| 在线国产一区二区在线| 久久欧美精品欧美久久欧美| 亚洲七黄色美女视频| 午夜福利成人在线免费观看| 亚洲 欧美 日韩 在线 免费| 午夜福利免费观看在线| 久久亚洲真实| 亚洲成a人片在线一区二区| 国产伦在线观看视频一区| 亚洲精品日韩av片在线观看 | 亚洲国产欧美网| 国产男靠女视频免费网站| 成人特级av手机在线观看| 99久久精品国产亚洲精品| 成人永久免费在线观看视频| 色噜噜av男人的天堂激情| 国产精品久久久久久人妻精品电影| 亚洲国产中文字幕在线视频| 久久精品91蜜桃| 五月玫瑰六月丁香| 99久久精品国产亚洲精品| 国产探花极品一区二区| 久久久成人免费电影| 久久久久九九精品影院| 亚洲欧美日韩高清在线视频| 男女午夜视频在线观看| 男女视频在线观看网站免费| 啦啦啦观看免费观看视频高清| 日韩免费av在线播放| 亚洲av电影在线进入| 夜夜夜夜夜久久久久| 天天一区二区日本电影三级| 天堂动漫精品| 国内精品久久久久久久电影| 久久国产精品影院| 99热只有精品国产| 夜夜夜夜夜久久久久| 亚洲国产精品合色在线| 国产欧美日韩精品亚洲av| 国产成人av教育| 久久久久免费精品人妻一区二区| 中文字幕人成人乱码亚洲影| 久久久国产成人免费| 在线播放无遮挡| 国产一区在线观看成人免费| 日韩亚洲欧美综合| 久久精品国产亚洲av涩爱 | 久久6这里有精品| 亚洲久久久久久中文字幕| 午夜两性在线视频| 听说在线观看完整版免费高清| www国产在线视频色| 成年版毛片免费区| 久久香蕉国产精品| 国产久久久一区二区三区| 亚洲一区二区三区色噜噜| 国产精品爽爽va在线观看网站| 最新在线观看一区二区三区| 白带黄色成豆腐渣| 亚洲精品色激情综合| av女优亚洲男人天堂| 9191精品国产免费久久| 国产欧美日韩一区二区三| 好男人在线观看高清免费视频| 人人妻人人看人人澡| 美女免费视频网站| 1024手机看黄色片| 白带黄色成豆腐渣| 一个人免费在线观看的高清视频| 色尼玛亚洲综合影院| 亚洲成人久久性| 最近视频中文字幕2019在线8| 中出人妻视频一区二区| 国语自产精品视频在线第100页| 午夜免费观看网址| 欧美黄色淫秽网站| 亚洲精品在线美女| 18禁美女被吸乳视频| 国内久久婷婷六月综合欲色啪| 色哟哟哟哟哟哟| 天天添夜夜摸| 观看免费一级毛片| 丁香欧美五月| 久久久色成人| 亚洲无线观看免费| АⅤ资源中文在线天堂| 蜜桃久久精品国产亚洲av| 亚洲中文字幕一区二区三区有码在线看| 成人特级av手机在线观看| 欧美日韩亚洲国产一区二区在线观看| 国产精品综合久久久久久久免费| 最近最新中文字幕大全免费视频| 蜜桃亚洲精品一区二区三区| 精品人妻一区二区三区麻豆 | 美女高潮喷水抽搐中文字幕| 国产亚洲精品久久久com| 国产久久久一区二区三区| 婷婷精品国产亚洲av| 欧美午夜高清在线| 51午夜福利影视在线观看| 久久性视频一级片| 亚洲天堂国产精品一区在线| 精品一区二区三区视频在线观看免费| 99精品欧美一区二区三区四区| tocl精华| 中文字幕人妻熟人妻熟丝袜美 | 少妇的逼好多水| 一区二区三区免费毛片| 校园春色视频在线观看| 日韩欧美在线乱码| 国产精品久久久久久亚洲av鲁大| 欧美黑人欧美精品刺激| 日韩欧美精品免费久久 | 久久人妻av系列| 少妇熟女aⅴ在线视频| 欧美日本亚洲视频在线播放| 亚洲无线在线观看| 日韩有码中文字幕| 脱女人内裤的视频| 亚洲人成网站在线播| 天天一区二区日本电影三级| 免费高清视频大片| 国产精品永久免费网站| 在线视频色国产色| 51国产日韩欧美| 激情在线观看视频在线高清| 18禁在线播放成人免费| 免费在线观看日本一区| 国产精品久久久久久精品电影| 在线免费观看不下载黄p国产 | 又黄又粗又硬又大视频| 亚洲精品粉嫩美女一区| 国产综合懂色| 美女免费视频网站| 99久久精品国产亚洲精品| 中文亚洲av片在线观看爽| 亚洲性夜色夜夜综合| 高清在线国产一区| 国产真人三级小视频在线观看| 亚洲五月婷婷丁香| 国产高清三级在线| av福利片在线观看| 在线视频色国产色| 亚洲狠狠婷婷综合久久图片| 熟女人妻精品中文字幕| 久久人妻av系列| 国产免费一级a男人的天堂| 国产黄色小视频在线观看| 亚洲av成人精品一区久久| 亚洲国产精品sss在线观看| 毛片女人毛片| 国产黄片美女视频| 国产伦人伦偷精品视频| 一级毛片高清免费大全| 五月玫瑰六月丁香| 制服人妻中文乱码| 欧美在线黄色| av片东京热男人的天堂| 日韩免费av在线播放| 一区二区三区免费毛片| 日韩精品中文字幕看吧| 香蕉丝袜av| 夜夜躁狠狠躁天天躁| 色噜噜av男人的天堂激情| 非洲黑人性xxxx精品又粗又长| 国产亚洲精品久久久久久毛片| 少妇裸体淫交视频免费看高清| 精品久久久久久久久久免费视频| 黄色女人牲交| 欧美极品一区二区三区四区| 人人妻人人澡欧美一区二区| 美女 人体艺术 gogo| 国产视频一区二区在线看| 国产黄色小视频在线观看| 国产精品野战在线观看| 欧美黑人欧美精品刺激| 级片在线观看| 男女做爰动态图高潮gif福利片| 亚洲成a人片在线一区二区| 色哟哟哟哟哟哟| 亚洲五月天丁香| 久久久久免费精品人妻一区二区| 午夜福利免费观看在线| 99久久精品一区二区三区| 日韩欧美一区二区三区在线观看| 精品99又大又爽又粗少妇毛片 | 亚洲成人免费电影在线观看| 久久精品91无色码中文字幕| 亚洲国产精品合色在线| 亚洲av第一区精品v没综合| 国产精品野战在线观看| 99在线人妻在线中文字幕| 国产高清videossex| 午夜福利18| 国产精品美女特级片免费视频播放器| 身体一侧抽搐| 国产亚洲av嫩草精品影院| 欧美日韩瑟瑟在线播放| 午夜亚洲福利在线播放| 国产亚洲精品一区二区www| 哪里可以看免费的av片| 人妻丰满熟妇av一区二区三区| 男女做爰动态图高潮gif福利片| 欧美黄色淫秽网站| 亚洲乱码一区二区免费版| 欧美日韩福利视频一区二区| 国内精品美女久久久久久| 中国美女看黄片| 在线十欧美十亚洲十日本专区| or卡值多少钱| 18+在线观看网站| 国产欧美日韩精品亚洲av| 天堂影院成人在线观看| 一进一出好大好爽视频| 在线播放国产精品三级| 啦啦啦免费观看视频1| 日本撒尿小便嘘嘘汇集6| 日韩欧美 国产精品| 美女cb高潮喷水在线观看| 国产精品99久久99久久久不卡| 国产伦人伦偷精品视频| 91在线观看av| 亚洲性夜色夜夜综合| 国产精品野战在线观看| 亚洲国产欧美人成| 精品久久久久久久人妻蜜臀av| 88av欧美| 精品久久久久久久久久免费视频| 岛国视频午夜一区免费看| 成人18禁在线播放| 日韩欧美一区二区三区在线观看| 国产精品永久免费网站| 一a级毛片在线观看| 欧美中文日本在线观看视频| 亚洲国产精品999在线| xxxwww97欧美| 波多野结衣高清无吗| 亚洲人成电影免费在线| 日韩免费av在线播放| 日韩欧美精品免费久久 | 国产欧美日韩精品一区二区| 黄片大片在线免费观看| a级一级毛片免费在线观看| 亚洲乱码一区二区免费版| 男插女下体视频免费在线播放| 国产精品亚洲美女久久久| 国产免费av片在线观看野外av| 精品熟女少妇八av免费久了| 国产伦在线观看视频一区| 老汉色av国产亚洲站长工具| 99久国产av精品| 一进一出抽搐gif免费好疼| 国产高清有码在线观看视频| 成人欧美大片| 久久精品国产亚洲av香蕉五月| av女优亚洲男人天堂| 欧美不卡视频在线免费观看| 亚洲精品色激情综合| 久99久视频精品免费| 老司机深夜福利视频在线观看| 久久精品国产亚洲av香蕉五月| 熟女人妻精品中文字幕| 岛国在线观看网站| 黄片小视频在线播放| 在线免费观看不下载黄p国产 | 免费搜索国产男女视频| 国产又黄又爽又无遮挡在线| 免费在线观看影片大全网站| 听说在线观看完整版免费高清| www.熟女人妻精品国产| 午夜福利高清视频| 精品免费久久久久久久清纯| 亚洲国产精品久久男人天堂| 一进一出抽搐gif免费好疼| 制服丝袜大香蕉在线| 国产又黄又爽又无遮挡在线| 国产精品影院久久| 久久精品91无色码中文字幕| 欧美最黄视频在线播放免费| 亚洲国产精品久久男人天堂| 欧美最新免费一区二区三区 | 亚洲一区二区三区色噜噜| 欧美性猛交黑人性爽| 99热这里只有精品一区| 一进一出抽搐gif免费好疼| 91在线精品国自产拍蜜月 | 久久婷婷人人爽人人干人人爱| 国产精品嫩草影院av在线观看 | 在线观看一区二区三区| 禁无遮挡网站| 天堂av国产一区二区熟女人妻| 啦啦啦免费观看视频1| 18美女黄网站色大片免费观看| 黑人欧美特级aaaaaa片| 欧美又色又爽又黄视频| 女人十人毛片免费观看3o分钟| 最新美女视频免费是黄的| 午夜免费成人在线视频| 欧美成人a在线观看| 亚洲在线观看片| 亚洲美女黄片视频| 天天躁日日操中文字幕| 午夜精品一区二区三区免费看| 国产精品久久久久久亚洲av鲁大| 夜夜爽天天搞| 欧美一级a爱片免费观看看| 女人高潮潮喷娇喘18禁视频| 岛国在线免费视频观看| 精品人妻一区二区三区麻豆 | 日韩欧美在线乱码| 国产不卡一卡二| 好男人在线观看高清免费视频| 国产亚洲精品一区二区www| 他把我摸到了高潮在线观看| 免费在线观看成人毛片| 亚洲成人免费电影在线观看| 黄色视频,在线免费观看| 丰满人妻熟妇乱又伦精品不卡| 中文字幕av成人在线电影| 免费搜索国产男女视频| 美女被艹到高潮喷水动态| 搡老岳熟女国产| 国产欧美日韩一区二区精品| 免费看光身美女| 长腿黑丝高跟| 婷婷丁香在线五月| 国产午夜福利久久久久久| 最近视频中文字幕2019在线8| 日本三级黄在线观看| 我的老师免费观看完整版| 91在线精品国自产拍蜜月 | 他把我摸到了高潮在线观看| 桃色一区二区三区在线观看| 欧美最新免费一区二区三区 | 中文字幕人妻丝袜一区二区| 国产精品 欧美亚洲| 人人妻,人人澡人人爽秒播| 亚洲最大成人手机在线| 国产毛片a区久久久久| 午夜亚洲福利在线播放| netflix在线观看网站| 亚洲激情在线av| 亚洲avbb在线观看| 亚洲美女黄片视频| 欧美极品一区二区三区四区| 国产精品98久久久久久宅男小说| 综合色av麻豆| 国内精品久久久久精免费| 久久久成人免费电影| 内地一区二区视频在线| 精品不卡国产一区二区三区| 有码 亚洲区| 国产亚洲av嫩草精品影院| 亚洲电影在线观看av| 在线观看午夜福利视频| 婷婷精品国产亚洲av| 久久天躁狠狠躁夜夜2o2o| 欧美最黄视频在线播放免费| 婷婷六月久久综合丁香| 欧洲精品卡2卡3卡4卡5卡区| 国内揄拍国产精品人妻在线| 亚洲精品456在线播放app | 久久人妻av系列| 最新中文字幕久久久久| 国产精品久久久久久久久免 | h日本视频在线播放| 嫩草影院入口| 国产伦精品一区二区三区四那| 国产国拍精品亚洲av在线观看 | 中国美女看黄片| 国产av麻豆久久久久久久| 亚洲,欧美精品.| 欧美中文综合在线视频| 无遮挡黄片免费观看| 国产麻豆成人av免费视频| 精品一区二区三区人妻视频| 最近最新免费中文字幕在线| 少妇熟女aⅴ在线视频| 极品教师在线免费播放| 一区二区三区国产精品乱码| 五月玫瑰六月丁香| 精品久久久久久久久久久久久| 男女下面进入的视频免费午夜| 成年女人毛片免费观看观看9| 伊人久久大香线蕉亚洲五| 精品一区二区三区视频在线 | 久久久精品欧美日韩精品| 亚洲在线观看片| 18禁国产床啪视频网站| www.熟女人妻精品国产| 午夜a级毛片| 夜夜夜夜夜久久久久| 国产精品国产高清国产av| 国产一区二区亚洲精品在线观看| 精品99又大又爽又粗少妇毛片 | 精品午夜福利视频在线观看一区| 999久久久精品免费观看国产| 精品久久久久久久末码| 成人永久免费在线观看视频| 国产三级黄色录像| 亚洲在线自拍视频| 亚洲片人在线观看| 亚洲第一欧美日韩一区二区三区| 精品人妻1区二区| bbb黄色大片| 1000部很黄的大片| 欧美xxxx黑人xx丫x性爽| 日韩精品中文字幕看吧| 日本免费a在线| 日韩有码中文字幕| 欧美三级亚洲精品| 欧美在线一区亚洲| 一个人看视频在线观看www免费 | 欧美日韩国产亚洲二区| 51午夜福利影视在线观看| 又黄又爽又免费观看的视频| 超碰av人人做人人爽久久 | 国产三级中文精品| 久9热在线精品视频| 一个人看的www免费观看视频| 国产精品自产拍在线观看55亚洲| 亚洲在线自拍视频| avwww免费| 欧美丝袜亚洲另类 | 免费看美女性在线毛片视频| 免费观看精品视频网站| 日韩欧美三级三区| av黄色大香蕉| 久久亚洲精品不卡| 久久精品国产99精品国产亚洲性色| 国产爱豆传媒在线观看| 亚洲成人久久爱视频| ponron亚洲| 好男人在线观看高清免费视频| 亚洲 欧美 日韩 在线 免费| 一边摸一边抽搐一进一小说| 99久久九九国产精品国产免费| 午夜亚洲福利在线播放| 欧美乱色亚洲激情| 最近视频中文字幕2019在线8| 亚洲国产欧美网| 色综合站精品国产| 日韩大尺度精品在线看网址| 日韩欧美一区二区三区在线观看| 欧美中文综合在线视频| 日本 av在线| 蜜桃久久精品国产亚洲av| 色噜噜av男人的天堂激情| 91麻豆av在线| 亚洲成人精品中文字幕电影| 很黄的视频免费| 国产99白浆流出| 俺也久久电影网| 亚洲成人免费电影在线观看| 欧美xxxx黑人xx丫x性爽| 成人高潮视频无遮挡免费网站| 51午夜福利影视在线观看| 亚洲欧美日韩东京热| 欧美在线一区亚洲| 亚洲欧美日韩东京热| 18禁在线播放成人免费| 在线观看舔阴道视频| 噜噜噜噜噜久久久久久91| 中文字幕av在线有码专区| 久久久久久久午夜电影| 午夜免费男女啪啪视频观看 | x7x7x7水蜜桃| 亚洲美女黄片视频| 日本三级黄在线观看| 亚洲精品色激情综合| 亚洲av中文字字幕乱码综合| 少妇裸体淫交视频免费看高清| 老熟妇乱子伦视频在线观看| 性色avwww在线观看| 一区二区三区高清视频在线| 日本撒尿小便嘘嘘汇集6| 欧美bdsm另类| 观看免费一级毛片| 国产精品三级大全| 一本综合久久免费| 国产黄色小视频在线观看| 亚洲va日本ⅴa欧美va伊人久久| 夜夜爽天天搞| 欧美三级亚洲精品| 给我免费播放毛片高清在线观看| 久久精品91蜜桃| 成人av在线播放网站| 97碰自拍视频| 精品午夜福利视频在线观看一区| 国产蜜桃级精品一区二区三区| 亚洲人成网站高清观看| 一个人免费在线观看的高清视频| 熟妇人妻久久中文字幕3abv| 欧美zozozo另类| 久久香蕉精品热| 亚洲五月婷婷丁香| 久久国产精品影院| 一区二区三区免费毛片| 国产精品亚洲一级av第二区| 黄片大片在线免费观看| 一区二区三区激情视频| 一区二区三区免费毛片| 日本成人三级电影网站| 一边摸一边抽搐一进一小说| 在线观看66精品国产| 中亚洲国语对白在线视频| 婷婷精品国产亚洲av| 一区二区三区免费毛片| av福利片在线观看| 国产精品久久视频播放| 三级男女做爰猛烈吃奶摸视频| 欧美黑人巨大hd| 亚洲av五月六月丁香网| 一边摸一边抽搐一进一小说| 日本黄大片高清| 国产亚洲av嫩草精品影院| 日韩欧美 国产精品| 成年免费大片在线观看| 国产一区二区在线观看日韩 | 少妇的丰满在线观看| 在线视频色国产色| 91麻豆av在线| 久久99热这里只有精品18| 国产在视频线在精品| 久久中文看片网| 亚洲人成网站高清观看| 亚洲熟妇中文字幕五十中出|